Post-Transplantation Osteoporosis

Endocrinology and Metabolism Clinics of North America

Volumn 36, Issue 4, 2007, Pages 937-963

  Stein, Emily ^a   Ebeling, Peter ^b   Shane, Elizabeth ^a  

^a College of Physicians and Surgeons ^*  (United States)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; AZATHIOPRINE; CALCITRIOL; CALCIUM; CYCLOSPORIN A; GLUCOCORTICOID; IBANDRONIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PAMIDRONIC ACID; PREDNISOLONE; PREDNISONE; RAPAMYCIN; RISEDRONIC ACID; TACROLIMUS; VITAMIN D;

BONE DISEASE; BONE MARROW TRANSPLANTATION; CHRONIC KIDNEY DISEASE; CHRONIC RESPIRATORY FAILURE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG INHIBITION; DRUG MEGADOSE; GENE EXPRESSION; HORMONE SUBSTITUTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; T LYMPHOCYTE; VITAMIN D DEFICIENCY;

BONE MARROW TRANSPLANTATION; DIPHOSPHONATES; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; ORGAN TRANSPLANTATION; OSTEOPOROSIS;

EID: 35648988990     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ecl.2007.07.008     Document Type: Review

References (121)

1. Shane E. Transplantation osteoporosis. In: Orwoll E., and Bliziotes M. (Eds). Osteoporosis: pathophysiology and clinical management (2003), Humana Press, Totowa (NJ) 537-567
2. Cohen A., and Shane E. Osteoporosis after solid organ and bone marrow transplantation. Osteoporos Int 14 8 (2003) 617-630
3. Cohen A., Sambrook P., and Shane E. Management of bone loss after organ transplantation. J Bone Miner Res 19 12 (2004) 1919-1932
4. Maalouf N.M., and Shane E. Osteoporosis after solid organ transplantation. J Clin Endocrinol Metab 90 4 (2005) 2456-2465
5. Kulak C.A., Borba V.Z., Kulak Jr. J., et al. Transplantation osteoporosis. Arq Bras Endocrinol Metabol 50 4 (2006) 783-792
6. Martin K., Al-Aly Z., and Gonzalez E. Renal osteodystrophy. In: Favus M. (Ed). Primer on the metabolic bone diseases and other disorders of bone and mineral metabolism, vol. 6 (2006), American Society for Bone and Mineral Research, Washington DC 359-366
7. Shane E., Mancini D., Aaronson K., et al. Bone mass, vitamin D deficiency and hyperparathyroidism in congestive heart failure. Am J Med 103 (1997) 197-207
8. Hay J.E. Osteoporosis in liver diseases and after liver transplantation. J Hepatol 38 6 (2003) 856-865
9. Monegal A., Navasa M., Guanabens N., et al. Bone disease after liver transplantation: a long-term prospective study of bone mass changes, hormonal status and histomorphometric characteristics. Osteoporos Int 12 6 (2001) 484-492
10. Sokhi R.P., Anantharaju A., Kondaveeti R., et al. Bone mineral density among cirrhotic patients awaiting liver transplantation. Liver Transpl 10 5 (2004) 648-653
11. Carey E.J., Balan V., Kremers W.K., et al. Osteopenia and osteoporosis in patients with end-stage liver disease caused by hepatitis C and alcoholic liver disease: not just a cholestatic problem. Liver Transpl 9 11 (2003) 1166-1173
12. Guichelaar M.M., Kendall R., Malinchoc M., et al. Bone mineral density before and after OLT: long-term follow-up and predictive factors. Liver Transpl 12 9 (2006) 1390-1402
13. Ninkovic M., Love S.A., Tom B., et al. High prevalence of osteoporosis in patients with chronic liver disease prior to liver transplantation. Calcif Tissue Int 69 6 (2001) 321-326
14. Aris R., Neuringer I., Weiner M., et al. Severe osteoporosis before and after lung transplantation. Chest 109 (1996) 1176-1183
15. Shane E., Silverberg S.J., Donovan D., et al. Osteoporosis in lung transplantation candidates with end stage pulmonary disease. Am J Med 101 (1996) 262-269
16. Tschopp O., Boehler A., Speich R., et al. Osteoporosis before lung transplantation: association with low body mass index, but not with underlying disease. Am J Transplant 2 2 (2002) 167-172
17. Aris R.M., Renner J.B., Winders A.D., et al. Increased rate of fractures and severe kyphosis: sequelae of living into adulthood with cystic fibrosis. Ann Intern Med 128 (1998) 186-193
18. Donovan Jr. D.S., Papadopoulos A., Staron R.B., et al. Bone mass and vitamin D deficiency in adults with advanced cystic fibrosis lung disease. Am J Respir Crit Care Med 157 6 Pt 1 (1998) 1892-1899
19. Ott S.M., and Aitken M.L. Osteoporosis in patients with cystic fibrosis. Clin Chest Med 19 3 (1998) 555-567
20. Tschopp O., Schmid C., Speich R., et al. Pretransplantation bone disease in patients with primary pulmonary hypertension. Chest 129 4 (2006) 1002-1008
21. Caplan-Shaw C.E., Arcasoy S.M., Shane E., et al. Osteoporosis in diffuse parenchymal lung disease. Chest 129 1 (2006) 140-146
22. Ebeling P.R. Bone disease after bone marrow transplantation. In: Compston J.E., and Shane E. (Eds). Bone disease of organ transplantation (2005), Elsevier, Academic Press, Burlington (MA) 339-352
23. Schulte C., Beelen D., Schaefer U., et al. Bone loss in long-term survivors after transplantation of hematopoietic stem cells: a prospective study. Osteoporos Int 11 (2000) 344-353
24. Valimaki M., Kinnunen K., Volin L., et al. A prospective study of bone loss and turnover after allogeneic bone marrow transplantation: effect of calcium supplementation with or without calcitonin. Bone Marrow Transplant 23 (1999) 355-361
25. Kananen K., Volin L., Laitinen K., et al. Prevention of bone loss after allogeneic stem cell transplantation by calcium, vitamin D, and sex hormone replacement with or without pamidronate. J Clin Endocrinol Metab 90 7 (2005) 3877-3885
26. Tauchmanova L., Selleri C., Rosa G.D., et al. High prevalence of endocrine dysfunction in long-term survivors after allogeneic bone marrow transplantation for hematologic diseases. Cancer 95 5 (2002) 1076-1084
27. van Staa T.P. The pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosis. Calcif Tissue Int 79 3 (2006) 129-137
28. Sun L., Blair H.C., Peng Y., et al. Calcineurin regulates bone formation by the osteoblast. Proc Natl Acad Sci U S A 102 47 (2005) 17130-17135
29. Sun L., Peng Y., Zaidi N., et al. Evidence that calcineurin is required for the genesis of bone-resorbing osteoclasts. Am J Physiol Renal Physiol 292 1 (2007) F285-F291
30. Awumey E., Moonga B., Sodam B., et al. Molecular and functional evidence for calcineurin alpha and beta isoforms in the osteoclasts. Novel insights into the mode of action of cyclosporine A. Biochem Biophys Res Commun 254 (1999) 248-252
31. Buchinsky F.J., Ma Y., Mann G.N., et al. T lymphocytes play a critical role in the development of cyclosporin A-induced osteopenia. Endocrinology 137 6 (1996) 2278-2285
32. Epstein S. Post-transplantation bone disease: the role of immunosuppressive agents on the skeleton. J Bone Miner Res 11 (1996) 1-7
33. Epstein S., Dissanayake A., Goodman G.R., et al. Effect of the interaction of parathyroid hormone and cyclosporine A on bone mineral metabolism in the rat. Calcif Tissue Int 68 (2001) 240-247
34. Bowman A.R., Sass D.A., Dissanayake I.R., et al. The role of testosterone in cyclosporine-induced osteopenia. J Bone Miner Res 12 4 (1997) 607-615
35. Ponticelli C., and Aroldi A. Osteoporosis after organ transplantation. Lancet 357 9268 (2001) 1623
36. Grotz W.H., Mundinger A., Gugel B., et al. Bone fracture and osteodensitometry with dual energy X-ray absorptiometry in kidney transplant recipients. Transplantation 58 (1994) 912-915
37. McIntyre H.D., Menzies B., Rigby R., et al. Long-term bone loss after renal transplantation: comparison of immunosuppressive regimens. Clin Transplant 9 1 (1995) 20-24
38. Cueto-Manzano A.M., Konel S., Crowley V., et al. Bone histopathology and densitometry comparison between cyclosporine A monotherapy and prednisolone plus azathioprine dual immunosuppression in renal transplant patients. Transplantation 75 12 (2003) 2053-2058
39. Josephson M.A., Schumm L.P., Chiu M.Y., et al. Calcium and calcitriol prophylaxis attenuates posttransplant bone loss. Transplantation 78 8 (2004) 1233-1236
40. Stempfle H.U., Werner C., Echtler S., et al. Rapid trabecular bone loss after cardiac transplantation using FK506 (tacrolimus)-based immunosuppression. Transplant Proc 30 4 (1998) 1132-1133
41. Park K.M., Hay J.E., Lee S.G., et al. Bone loss after orthotopic liver transplantation: FK 506 versus cyclosporine. Transplant Proc 28 3 (1996) 1738-1740
42. Goffin E., Devogelaer J.P., Lalaoui A., et al. Tacrolimus and low-dose steroid immunosuppression preserves bone mass after renal transplantation. Transpl Int 15 2-3 (2002) 73-80
43. Monegal A., Navasa M., Guanabens N., et al. Bone mass and mineral metabolism in liver transplant patients treated with FK506 or cyclosporine A. Calcif Tissue Int 68 (2001) 83-86
44. Campistol J.M., Holt D.W., Epstein S., et al. Bone metabolism in renal transplant patients treated with cyclosporine or sirolimus. Transpl Int 18 9 (2005) 1028-1035
45. Chou N.K., Su I.C., Kuo H.L., et al. Bone mineral density in long-term Chinese heart transplant recipients: a cross-sectional study. Transplant Proc 38 7 (2006) 2141-2144
46. Cohen A., Addonizio L.J., Lamour J.M., et al. Osteoporosis in adult survivors of adolescent cardiac transplantation may be related to hyperparathyroidism, mild renal insufficiency, and increased bone turnover. J Heart Lung Transplant 24 6 (2005) 696-702
47. Cohen A., and Shane E. Bone disease in patients before and after cardiac transplantation. In: Compston J.E., and Shane E. (Eds). Bone disease of organ transplantation (2005), Elsevier Academic Press, Burlington (MA) 287-301
48. Shane E., Addesso V., Namerow P.B., et al. Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation. N Engl J Med 350 8 (2004) 767-776
49. Shane E., Rivas M., Staron R.B., et al. Fracture after cardiac transplantation: a prospective longitudinal study. J Clin Endocrinol Metab 81 (1996) 1740-1746
50. Leidig-Bruckner G., Hosch S., Dodidou P., et al. Frequency and predictors of osteoporotic fractures after cardiac or liver transplantation: a follow-up study. Lancet 357 (2001) 342-347
51. Compston J.E. Osteoporosis after liver transplantation. Liver Transpl 9 4 (2003) 321-330
52. Maalouf N.M., and Sakhaee K. Treatment of osteoporosis in patients with chronic liver disease and in liver transplant recipients. Curr Treat Options Gastroenterol 9 6 (2006) 456-463
53. Ninkovic M., Love S., Tom B.D., et al. Lack of effect of intravenous pamidronate on fracture incidence and bone mineral density after orthotopic liver transplantation. J Hepatol 37 1 (2002) 93-100
54. Floreani A., Mega A., Tizian L., et al. Bone metabolism and gonad function in male patients undergoing liver transplantation: a two-year longitudinal study. Osteoporos Int 12 9 (2001) 749-754
55. Smallwood G.A., Burns D., Fasola C.G., et al. Relationship between immunosuppression and osteoporosis in an outpatient liver transplant clinic. Transplant Proc 37 4 (2005) 1910-1911
56. Shah S.H., Johnston T.D., Jeon H., et al. Effect of chronic glucocorticoid therapy and the gender difference on bone mineral density in liver transplant patients. J Surg Res 135 2 (2006) 238-241
57. Millonig G., Graziadei I.W., Eichler D., et al. Alendronate in combination with calcium and vitamin D prevents bone loss after orthotopic liver transplantation: a prospective single-center study. Liver Transpl 11 8 (2005) 960-966
58. Ninkovic M., Skingle S.J., Bearcroft P.W., et al. Incidence of vertebral fractures in the first three months after orthotopic liver transplantation. Eur J Gastroenterol Hepatol 12 8 (2000) 931-935
59. Fabrega E., Orive A., Garcia-Unzueta M., et al. Osteoprotegerin and receptor activator of nuclear factor-kappaB ligand system in the early post-operative period of liver transplantation. Clin Transplant 20 3 (2006) 383-388
60. Epstein S., and Shane E. In: Marcus R., Feldman D., and Kelsey J. (Eds). Osteoporosis. Transplantation osteoporosis vol. 2 (2001), Academic Press, San Diego (CA) 327-340
61. Shane E., and Epstein S. Transplantation osteoporosis. Transplant Rev 15 1 (2001) 11-32
62. Rutherford R.M., Fisher A.J., Hilton C., et al. Functional status and quality of life in patients surviving 10 years after lung transplantation. Am J Transplant 5 5 (2005) 1099-1104
63. Spira A., Gutierrez C., Chaparro C., et al. Osteoporosis and lung transplantation: a prospective study. Chest 117 2 (2000) 476-481
64. Shane E., Papadopoulos A., Staron R.B., et al. Bone loss and fracture after lung transplantation. Transplantation 68 (1999) 220-227
65. Haworth C.S., Webb A.K., Egan J.J., et al. Bone histomorphometry in adult patients with cystic fibrosis. Chest 118 2 (2000) 434-439
66. Banfi A., Podesta M., Fazzuoli L., et al. High-dose chemotherapy shows a dose-dependent toxicity to bone marrow osteoprogenitors: a mechanism for post-bone marrow transplantation osteopenia. Cancer 92 9 (2001) 2419-2428
67. Lee W.Y., Cho S.W., Oh E.S., et al. The effect of bone marrow transplantation on the osteoblastic differentiation of human bone marrow stromal cells. J Clin Endocrinol Metab 87 1 (2002) 329-335
68. Kang M.I., Lee W.Y., Oh K.W., et al. The short-term changes of bone mineral metabolism following bone marrow transplantation. Bone 26 3 (2000) 275-279
69. Ebeling P., Thomas D., Erbas B., et al. Mechanism of bone loss following allogeneic and autologous hematopoietic stem cell transplantation. J Bone Miner Res 14 (1999) 342-350
70. Lee W.Y., Kang M.I., Baek K.H., et al. The skeletal site-differential changes in bone mineral density following bone marrow transplantation: 3-year prospective study. J Korean Med Sci 17 6 (2002) 749-754
71. Tauchmanova L., Serio B., Del Puente A., et al. Long-lasting bone damage detected by dual-energy x-ray absorptiometry, phalangeal osteosonogrammetry, and in vitro growth of marrow stromal cells after allogeneic stem cell transplantation. J Clin Endocrinol Metab 87 11 (2002) 5058-5065
72. Nysom K., Holm K., Michaelsen K.F., et al. Bone mass after allogeneic BMT for childhood leukaemia or lymphoma. Bone Marrow Transplant 25 2 (2000) 191-196
73. Gandhi M.K., Lekamwasam S., Inman I., et al. Significant and persistent loss of bone mineral density in the femoral neck after haematopoietic stem cell transplantation: long-term follow-up of a prospective study. Br J Haematol 121 3 (2003) 462-468
74. Lee W.Y., Kang M.I., Oh E.S., et al. The role of cytokines in the changes in bone turnover following bone marrow transplantation. Osteoporos Int 13 1 (2002) 62-68
75. Michelson J.D., Gornet M., Codd T., et al. Bone morphology after bone marrow transplantation for Hodgkin's and non- Hodgkin's lymphoma. Exp Hematol 21 3 (1993) 475-482
76. Athanasou N.A., Quinn J., Brenner M.K., et al. Origin of marrow stromal cells and haemopoietic chimaerism following bone marrow transplantation determined by in situ hybridisation. Br J Cancer 61 3 (1990) 385-389
77. Kananen K., Volin L., Tahtela R., et al. Recovery of bone mass and normalization of bone turnover in long-term survivors of allogeneic bone marrow transplantation. Bone Marrow Transplant 29 1 (2002) 33-39
78. Arekat M.R., And G., Lemke S., et al. Dramatic improvement of BMD following vitamin D therapy in a bone marrow transplant recipient. J Clin Densitom 5 3 (2002) 267-271
79. Hattori M., Morita N., Tsujino Y., et al. Vitamins D and K in the treatment of osteoporosis secondary to graft-versus-host disease following bone-marrow transplantation. J Int Med Res 29 4 (2001) 381-384
80. Tauchmanova L., De Rosa G., Serio B., et al. Avascular necrosis in long-term survivors after allogeneic or autologous stem cell transplantation: a single center experience and a review. Cancer 97 10 (2003) 2453-2461
81. Shirsat M, Josephson MA, Sprague SM. Vitamin D deficiency following renal transplantation. J Am Soc Nephrol, in press.
82. Briffa N.K., Keogh A.M., Sambrook P.N., et al. Reduction of immunosuppressant therapy requirement in heart transplantation by calcitriol. Transplantation 75 12 (2003) 2133-2134
83. Lemire J.M. Immunomodulatory role of 1,25 Dihydroxyvitamin D3. J Cell Biochem 49 (1992) 26-31
84. Lemire J.M., Archer D.C., and Reddy G.S. Dihydroxy-24-oxo-16-ene-vitamin D3, a renal metabolite of the vitamin D analog 1,25-dihydroxy-16ene-vitamin D3, exerts immunosuppressive activity equal to its parent without causing hypercalcemia in vivo. Endocrinology 135 (1994) 2818-2821
85. El-Agroudy A.E., El-Husseini A.A., El-Sayed M., et al. Preventing bone loss in renal transplant recipients with vitamin D. J Am Soc Nephrol 14 11 (2003) 2975-2979
86. De Sevaux R.G., Hoitsma A.J., Corstens F.H., et al. Treatment with vitamin D and calcium reduces bone loss after renal transplantation: a randomized study. J Am Soc Nephrol 13 6 (2002) 1608-1614
87. El-Agroudy A.E., El-Husseini A.A., El-Sayed M., et al. A prospective randomized study for prevention of postrenal transplantation bone loss. Kidney Int 67 5 (2005) 2039-2045
88. Sambrook P., Henderson N.K., Keogh A., et al. Effect of calcitriol on bone loss after cardiac or lung transplantation. J Bone Miner Res 15 9 (2000) 1818-1824
89. Stempfle H.U., Werner C., Echtler S., et al. Prevention of osteoporosis after cardiac transplantation: a prospective, longitudinal, randomized, double-blind trial with calcitriol. Transplantation 68 4 (1999) 523-530
90. Stempfle H.U., Werner C., Siebert U., et al. The role of tacrolimus (FK506)-based immunosuppression on bone mineral density and bone turnover after cardiac transplantation: a prospective, longitudinal, randomized, double-blind trial with calcitriol. Transplantation 73 4 (2002) 547-552
91. Aris R.M., Lester G.E., Renner J.B., et al. Efficacy of pamidronate for osteoporosis in patients with cystic fibrosis following lung transplantation. Am J Respir Crit Care Med 162 3 Pt 1 (2000) 941-946
92. Bianda T., Linka A., Junga G., et al. Prevention of osteoporosis in heart transplant recipients: a comparison of calcitriol with calcitonin and pamidronate. Calcif Tissue Int 67 (2000) 116-121
93. Fan S., Almond M.K., Ball E., et al. Pamidronate therapy as prevention of bone loss following renal transplantation. Kidney Int 57 (2000) 684-690
94. Shane E., Rodino M.A., McMahon D.J., et al. Prevention of bone loss after heart transplantation with antiresorptive therapy: a pilot study. J Heart Lung Transplant 17 11 (1998) 1089-1096
95. Hommann M., Abendroth K., Lehmann G., et al. Effect of transplantation on bone: osteoporosis after liver and multivisceral transplantation. Transplant Proc 34 6 (2002) 2296-2298
96. Grotz W., Nagel C., Poeschel D., et al. Effect of ibandronate on bone loss and renal function after kidney transplantation. J Am Soc Nephrol 12 7 (2001) 1530-1537
97. Arlen D.J., Lambert K., Ioannidis G., et al. Treatment of established bone loss after renal transplantation with etidronate. Transplantation 71 5 (2001) 669-673
98. Trombetti A., Gerbase M.W., Spiliopoulos A., et al. Bone mineral density in lung-transplant recipients before and after graft: prevention of lumbar spine post-transplantation-accelerated bone loss by pamidronate. J Heart Lung Transplant 19 8 (2000) 736-743
99. Krieg M., Seydoux C., Sandini L., et al. Intravenous pamidronate as a treatment for osteoporosis after heart transplantation: a prospective study. Osteoporos Int 12 (2001) 112-116
100. Haas M., Leko-Mohr Z., Roschger P., et al. Zoledronic acid to prevent bone loss in the first 6 months after renal transplantation. Kidney Int 63 3 (2003) 1130-1136
101. Coco M., Glicklich D., Faugere M.C., et al. Prevention of bone loss in renal transplant recipients: a prospective, randomized trial of intravenous pamidronate. J Am Soc Nephrol 14 10 (2003) 2669-2676
102. Pennisi P., Trombetti A., Giostra E., et al. Pamidronate and osteoporosis prevention in liver transplant recipients. Rheumatol Int 27 3 (2007) 251-256
103. Crawford B.A., Kam C., Pavlovic J., et al. Zoledronic acid prevents bone loss after liver transplantation: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 144 4 (2006) 239-248
104. Ippoliti G., Pellegrini C., Campana C., et al. Clodronate treatment of established bone loss in cardiac recipients: a randomized study. Transplantation 75 3 (2003) 330-334
105. Kovac D., Lindic J., Kandus A., et al. Prevention of bone loss in kidney graft recipients. Transplant Proc 33 1-2 (2001) 1144-1145
106. Giannini S., Dangel A., Carraro G., et al. Alendronate prevents further bone loss in renal transplant recipients. J Bone Miner Res 16 11 (2001) 2111-2117
107. Jeffery J.R., Leslie W.D., Karpinski M.E., et al. Prevalence and treatment of decreased bone density in renal transplant recipients: a randomized prospective trial of calcitriol versus alendronate. Transplantation 76 10 (2003) 1498-1502
108. Koc M., Tuglular S., Arikan H., et al. Alendronate increases bone mineral density in long-term renal transplant recipients. Transplant Proc 34 6 (2002) 2111-2113
109. Cohen A., Addesso V., McMahon D.J., et al. Discontinuing antiresorptive therapy one year after cardiac transplantation: effect on bone density and bone turnover. Transplantation 81 5 (2006) 686-691
110. Atamaz F., Hepguler S., Karasu Z., et al. The prevention of bone fractures after liver transplantation: experience with alendronate treatment. Transplant Proc 38 5 (2006) 1448-1452
111. Grigg A.C., Shuttleworth P., Reynolds J., et al. Pamidronate therapy for one year after allogeneic bone marrow transplantation (AlloBMT) reduces bone loss from the lumbar spine, femoral neck and total hip. Blood 104 (2004) A2253
112. Ebeling P.R. Defective osteoblast function may be responsible for bone loss from the proximal femur despite pamidronate therapy. J Clin Endocrinol Metab 90 7 (2005) 4414-4416
113. Tauchmanova L., Selleri C., Esposito M., et al. Beneficial treatment with risedronate in long-term survivors after allogeneic stem cell transplantation for hematological malignancies. Osteoporos Int 14 12 (2003) 1013-1019
114. Tauchmanova L., Ricci P., Serio B., et al. Short-term zoledronic acid treatment increases bone mineral density and marrow clonogenic fibroblast progenitors after allogeneic stem cell transplantation. J Clin Endocrinol Metab 90 2 (2005) 627-634
115. D'Souza A.B., Grigg A.P., Szer J., et al. Zoledronic acid prevents bone loss after allogeneic haemopoietic stem cell transplantation. Int Med J 36 (2006) 600-603
116. Isoniemi H., Appelberg J., Nilsson C.G., et al. Transdermal oestrogen therapy protects postmenopausal liver transplant women from osteoporosis. A 2-year follow-up study. J Hepatol 34 2 (2001) 299-305
117. Branco C.C., Rovira M., Pons F., et al. The effect of hormone replacement therapy on bone mass in patients with ovarian failure due to bone marrow transplantation. Maturitas 23 (1996) 307-312
118. Fahrleitner A., Prenner G., Tscheliessnigg K.H., et al. Testosterone supplementation has additional benefits on bone metabolism in cardiac transplant recipients receiving intravenous bisphosphonate treatment: a prospective study. J Bone Miner Res 17 Suppl 1 (2002) S388
119. Braith R.W., Conner J.A., Fulton M.N., et al. Comparison of alendronate vs alendronate plus mechanical loading as prophylaxis for osteoporosis in lung transplant recipients: a pilot study. J Heart Lung Transplant 26 2 (2007) 132-137
120. Braith R.W., Magyari P.M., Fulton M.N., et al. Comparison of calcitonin versus calcitonin + resistance exercise as prophylaxis for osteoporosis in heart transplant recipients. Transplantation 81 8 (2006) 1191-1195
121. Hommann M., Kammerer D., Lehmann G., et al. Prevention of early loss of bone mineral density after liver transplantation by prostaglandin E1. Transplant Proc 39 2 (2007) 540-543